Denali Regains Full Control Of DNL593 As It Advances Toward Key 2026 Readout

Denali Therapeutics regained full rights to DNL593 (PTV:PGRN), its progranulin replacement candidate for GRN-related frontotemporal dementia, after Takeda terminated the co-development agreement. The company now holds exclusive control of development and commercialization, shifting development cost and regulatory risk back to Denali; no financial terms or timeline were disclosed. Absent additional clinical or financing details, this is unlikely to have a large market impact in the near term.

Analysis

Denali Therapeutics regained full rights to DNL593 (PTV:PGRN), its progranulin replacement candidate for GRN-related frontotemporal dementia, after Takeda terminated the co-development agreement. The company now holds exclusive control of development and commercialization, shifting development cost and regulatory risk back to Denali; no financial terms or timeline were disclosed. Absent additional clinical or financing details, this is unlikely to have a large market impact in the near term.